AbbVie Immunology
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 11 disclosed transactions, AbbVie Immunology concentrates its licensing activity in Oncology, Neurology, and Mega Deals. AbbVie Immunology pays a 1.50x premium over market median. Their most common deal structure is Option, with an average disclosed value of $3.7B. Most recent activity: 2026.
Pipeline coverage & gaps
AbbVie Immunology has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| OptionPrimary | 6 | $33M | $1.1B |
| Acquisition | 2 | — | $10.9B |
| Co Development | 2 | $35M | $3.0B |
| License | 1 | — | $5.6B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | RC148 | RemeGen | advanced solid tumors | unknown | — | $5.6B |
| 2026 | VivoVec CAR-T candidates | Umoja Biopharma | oncology | unknown | — | $1.4B |
| 2026 | Apogee Therapeutics portfolio (Dupixent competitor / long-acting autoimmune biologics) | Apogee Therapeutics | atopic dermatitis and type-2 inflammatory / autoimmune diseases | phase_3 | — | $11.0B |
| 2026 | APG777 | Apogee Therapeutics | atopic dermatitis | preclinical | — | $10.9B |
| 2025 | trispecific T-cell engager | Simcere Zaimin | multiple myeloma | phase_1 | — | $1.1B |
| 2025 | SIM0500 | Simcere Pharmaceutical | blood cancer | unknown | — | $1.1B |
| 2025 | SIM0500 | Simcere | blood cancer | unknown | — | $1.1B |
| 2024 | Long-acting injectable products (up to six) | MedinCell | multiple indications | preclinical | $35M | $1.9B |
| 2024 | next-gen neuroscience therapeutics | Gilgamesh Pharmaceuticals | psychiatry | unknown | — | $4.0B |
| 2024 | psychiatric disorder therapies | Gilgamesh | psychiatric disorders | unknown | $65M | $2.0B |
| 2023 | reproxalap | Aldeyra Therapeutics | dry eye | unknown | $1M | $100M |
How this is computed
For each AbbVie Immunology deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.517, clamped to [0.7, 1.5].